Search Results - PHARMACOECONOMICS

1

Modeling microbial drug-resistance: from mathematics to pharmacoeconomics

by Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko
Published 2018-05-01

Get full text

Article

2

Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases

by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
Published 2018-05-01

Subjects: “...pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases...”

Get full text

Article

3

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation

by A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin
Published 2018-05-01

Subjects: “...pharmacoeconomics...”

Get full text

Article

4

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation

by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin
Published 2018-05-01

Get full text

Article

5

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases

by A. S. Kolbin, A. A. Kurylev, Y. E. Balykina, M. A. Proskurin
Published 2019-04-01

Subjects: “...pharmacoeconomics...”

Get full text

Article

6

Analysis of effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the essential drug list in 2014-2016 in Russia

by A. A. Mosikyan, A. A. Kurylev, A. S. Kolbin
Published 2018-05-01

Subjects: “...pharmacoeconomics...”

Get full text

Article

7

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa...

by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, D. R. Naskhletashvili
Published 2018-05-01

Get full text

Article

8

Economic analysis of Lixisenatide in Diabetes Mellitus Type 2

by A. S. Kolbin, A. A. Mosikyan, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, W. Zhao
Published 2018-05-01

Subjects: “...pharmacoeconomics...”

Get full text

Article

9

FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS

by A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
Published 2015-03-01

“... conditions and to perform pharmacoeconomic evaluation of glucose lowering therapies. Materials and methods...”

Get full text

Article

10

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE

by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
Published 2016-12-01

Get full text

Article

11

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016

by A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
Published 2016-04-01

Get full text

Article

12

What is the role of antineoplastic drug safety in reimbursement decision making?

by A. S. Kolbin, A. A. Kurylev
Published 2018-11-01

Get full text

Article

13

The social-economic burden of spinal muscular atrophy in Russia

by A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina
Published 2021-02-01

Get full text

Article

14

Overview of mathematical models of breast cancer

by Yu. P. Yurkova, A. A. Kurylev, A. S. Kolbin
Published 2019-10-01

“... be divided into groups: pharmacoeconomic model of particular drug, BC screening models, model of tumor growth...”

Get full text

Article

Narrow Search